Latest From Colgate-Palmolive Co.
Industry and the FDA agree that the OTC drug monograph system is direly in need of reform, but innovating with noncompliant dosage forms and indications, without approved new drug applications, is a risk companies need to weigh seriously, says Arnall Golden Gregory partner Alan Minsk. The FDA offers perspective on its OTC monographs for acne and antiperspirant products.
CHPA appoints Anne Marie Murphy deputy general counsel; CRN promotes Andrew Wong to senior VP, scientific and regulatory affairs; and Sarah Michelle Gellar promotes the Colgate Optic White High Impact line.
Wellness Market Executive Decisions: Beckham For Pedialyte, 'Gronk' For CBD, Honderd Out At Mary's, Appointments At GB Sciences, Nature's Bounty
Cleveland Browns' Beckham promotes Pedialyte for all; Pfizer consumer execTahiri heads Nature 's Bounty international business;GB Sciences adds cannabis operations expert; Honderd steps away at Mary's Brands; and 'Gronk' invests in CBD product firm, begins product development.
Colgate changing to be more “agile” and predictive of local trends while also cutting product development time significantly, says CEO Noel Wallace. Approach has worked well in natural toothpaste business, where firm is gaining market share with toothpastes appealing to local preferences.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Colgate-Palmolive Co.
- Senior Management
Ian Cook, Chmn., Pres. & CEO
Dennis Hickey, CFO
Lois Juliber, EVP, Chief, Operations, Developed Mkts.
John Reid, CTO
William S Shanahan, Pres. & COO
- Contact Info
Phone: (212) 310-2000
300 Park Ave.
New York, NY 10022-7499
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.